US SEC Trading Suspension Halt Orders — July 16, 2026

Regained full compliance with NYSE American listing standards, resolving a deficiency from October 2025. This removes immediate delisting risk and could restore investor confidence, potentially leading to a re-rating

Received delisting determination from Nasdaq due to bid price below $1.00 for 31 consecutive days; ineligible for compliance period due to prior reverse split. Hearing request deadline is July 17, 2026—failure to act leads to suspension on July 21

Received three Nasdaq deficiency notices (bid price, market value of publicly held shares, listed securities) but has 180 days until January 11, 2027 to regain compliance. This provides a window for potential corrective actions [NEUTRAL/BEARISH]

No insider buying or capital allocation activity reported in filing, suggesting lack of management confidence or financial flexibility to address the delisting

Positive compliance resolution without any disclosed reverse split or capital restructuring, indicating organic improvement in financial metrics

Multiple compliance failures (bid price, market cap) signal underlying financial stress; no insider transactions or forward guidance provided to offset concerns

Trading suspension expected July 21, 2026 if hearing not requested—immediate catalyst for price decline and loss of liquidity

Compliance resolution could attract new investors and improve access to capital markets, supporting future growth

Nasdaq delisting determination effective July 21, 2026 unless hearing requested by July 17. Stock already trading below $1.00 for 31 consecutive days; prior reverse split in October 2025 failed to sustain compliance

Non-compliance with three Nasdaq rules simultaneously (bid price, market value of publicly held shares, market value of listed securities) indicates severe market capitalization erosion and liquidity issues

Ineligible for standard 180-day cure due to reverse stock split within past year, leaving no regulatory buffer—immediate delisting path

Minimum $15M publicly held shares and $50M listed securities thresholds breached, suggesting significant shareholder value destruction

No assurance of favorable outcome from Nasdaq Hearings Panel; even if granted, suspension may still occur

Status as emerging growth company may limit ability to raise capital quickly to address compliance issues

Absence of insider buying or capital actions (buybacks, dividends) suggests management may lack resources or conviction to save listing

All companies are small-cap or micro-cap, inherently more vulnerable to price swings and liquidity shocks from regulatory actions

Regained NYSE American compliance without reverse split—potential for positive revaluation as delisting overhang removed; watch for subsequent earnings or operational updates

180-day compliance period until January 11, 2027 provides time for management to implement corrective actions (reverse split, capital raise, business improvements); monitor for announcements

If hearing is requested by July 17, trading suspension is stayed; potential short-term trading opportunity if market overreacts to delisting news

Positive compliance event stands out against negative delisting news from peers, potentially attracting rotational capital from risk-averse investors

Company can address any one of the three deficiencies to regain compliance—flexibility in strategy (e.g., reverse split for bid price, business improvement for market cap)

If delisted, stock may trade OTC; distressed investors could find value if underlying business is sound, though high risk

Trading suspensions create volatility that active traders can exploit with proper risk management; focus on dates (July 17, 21 for Cycurion; January 11, 2027 for OBAI)

Two of three filings involve Nasdaq non-compliance, highlighting persistent challenges for small-cap companies to maintain exchange listing standards post-2020 volatility

Cycurion's prior reverse split (1-for-30) failed to sustain bid price above $1.00, illustrating that reverse splits often provide only temporary relief without fundamental improvement

The stream shows stark divergence—one company regains compliance (SRXH), one faces imminent delisting (Cycurion), one has a cure window (OBAI)—emphasizing the binary nature of exchange compliance events

None of the filings disclosed insider transactions or capital allocation actions, suggesting management teams in distressed micro-caps may lack resources or confidence to signal support

SRXH's compliance on NYSE American contrasts with Nasdaq's stricter enforcement for Cycurion and OBAI, potentially reflecting different exchange tolerance or company-specific factors

July 17, 2026 deadline to request Nasdaq hearing; failure leads to suspension July 21. Monitor for 8-K filing confirming request

July 21, 2026 expected suspension if no hearing; watch for OTC trading symbol if delisted

180-day period ends January 11, 2027; monitor for reverse split announcements, capital raises, or business updates

Next earnings release may provide operational context for compliance recovery; watch for revenue or margin improvements

Inclusion expected within 5 business days of July 14 notification; monitor for trading volume and price impact

If hearing requested, panel decision timeline uncertain; watch for updates on outcome and any extension granted

Any subsequent Form 4 filings would provide critical signal of management conviction post-compliance events